NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

We have a saying in the industry... time is money.

When your products have a finite patent life and competition can drastically reduce revenue, every day you are not on the market is lost revenue. Since this is a condition where patients die, there is no future opportunity to recover this revenue. It is truly lost . This is not cold, it is just truth.

In the case of Nov 18 through summer 2020, the time there was not lost as it led to a change in SAP that drastically improves approval potential. This could have a huge positive impact on revenue. The problem now is that the company has no Public explanation that supports further patience on top line results. That does not mean that one does not exist, they just haven’t given reason. I know all about the publication yada yada. In and of itself, this is not a good rationale as most every other drug releases data and often even receives approval before study publication because time is money.